Dear Pompe Patient Community,

As Audentes continues to advance its investigational gene therapy candidate for Pompe disease, we want to provide you with an important update on the program. We hope you find this information helpful.

**POMPE PROGRAM UPDATE**

Audentes is now enrolling patients in FORTIS, an open-label, ascending dose, multicenter Phase 1/2 clinical trial to evaluate its investigational gene therapy product candidate in participants who are 18 years of age or older, ambulatory or non-ambulatory, with late-onset Pompe disease (LOPD).

**FAQs**

Following are frequently asked questions about Audentes’ investigational gene therapy product candidate for the treatment of LOPD and the clinical trial FORTIS.

**Q: How does Audentes’ investigational gene therapy product work?**
**A:** This investigational gene therapy product is comprised of a working copy of the GAA gene, and the new gene is placed inside a vector, which acts as a transportation vehicle and carries the gene to the appropriate cells in the body. A virus is selected as a vector because of its ability to enter the body’s cells. In this case, a very small and simple virus called adeno-associated virus (AAV) is used because it is not known to cause viral illness in people. The vector is administered one time through an intravenous injection and carries the new gene to the control center of the cells, also known as the nucleus. Once inside the muscle cell nucleus, the new gene tells the body’s cells how to make the protein, or GAA, it needs.

![Diagram of gene therapy process](image)

**Q: How does Audentes’ investigational gene therapy approach differ from other approved treatments and investigational gene therapies?**
**A:** The goal of Audentes’ investigational gene therapy approach is to express GAA preferentially in muscle tissues, including skeletal and cardiac muscle, which are the tissues most affected by the disease.

This approach differs from approved enzyme replacement therapy (ERT) and liver-directed investigational gene therapy candidates that must overcome the challenges of GAA uptake into muscle from plasma, a liquid that makes up about half of the content of blood. The main role of plasma is to take nutrients, hormones, and proteins to the parts of the body that need it. In the case of liver-directed gene therapy products, plasma transports GAA from the liver to the muscle tissue. The ERT and liver-directed approaches leverage a delivery system that may impact the amount and distribution of GAA in the muscle tissue.
**Q: What are the objectives of FORTIS?**
**A:** The objectives of the clinical trial are to evaluate the following:

- The safety of 2 dose levels of the investigational gene therapy product in trial participants 18 years of age or older with LOPD
- Acid alpha-glucosidase (GAA) activity and preliminary efficacy of 2 dose levels of the investigational gene therapy product in participants 18 years of age with LOPD

**Q: How many people will take part in this investigative clinical trial?**
**A:** Up to approximately 8 people are expected to be in this trial in North America and Europe. Patients who meet eligibility are not guaranteed enrollment into the trial.

For specific clinical trial site information, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and enter “Pompe” in the “condition or disease” section and “FORTIS” in the “other terms” section. Click on “Gene Transfer Study in Patients with Late Onset Pompe Disease.”

**Q: Who is eligible to participate in the clinical trial?**
**A:** To confirm participation in this clinical trial, a trial site doctor will review the following information from an individual’s medical records:

- Diagnosis of Pompe disease
- Medication use: The only approved treatment for Pompe disease is ERT with recombinant human GAA (Lumizyme®, Myozyme®). To be able to take part in this clinical trial, you need to have been receiving Lumizyme® or Myozyme® for at least 2 years and on a stable dose for the last 6 months.
- Pulmonary (breathing) function
- Review of other medical conditions

*Other criteria will apply.*

For clinical trial inclusion/exclusion criteria, please visit please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and enter “Pompe” in the “condition or disease” section and “FORTIS” in the “other terms” section. Click on “Gene Transfer Study in Patients with Late Onset Pompe Disease.”

**Q: What are the benefits of participating in FORTIS?**
**A:** It is not known if being in this investigational clinical trial will improve an individual’s condition; however, being in the trial may lead to having more frequent visits, testing, and evaluation by experts in Pompe disease. Additionally, other patients may benefit from knowledge gained – about Pompe disease or gene therapy in general – from this clinical trial.

---

**FOR MORE INFORMATION ON FORTIS**

Talk to your doctor to find out if you might be eligible to participate in the FORTIS clinical trial and to learn the benefits and risk of participating in the trial. You also may reach out to the clinical trial sites listed on [www.clinicaltrials.gov](http://www.clinicaltrials.gov). To view the FORTIS clinical trial on the website, enter “Pompe” in the “condition or disease” section and “FORTIS” in the “other terms” section. Click on “Gene Transfer Study in Patients with Late Onset Pompe Disease.” The ClinicalTrials.gov identifier (NCT number) for FORTIS is NCT04174105.
Audentes Therapeutics, an Astellas company, is developing genetic medicines with the potential to deliver transformative value for patients. Based on our innovative scientific approach and industry-leading internal manufacturing capability and expertise, we have become the Astellas Center of Excellence for the newly created Genetic Regulation Focus Area. We are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown, with plans to expand our focus and geographic reach under Astellas. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.”

Thank you to the community for your input on the protocol and inclusion criteria for FORTIS. Your meaningful insights made all the difference, and we incorporated as much of your feedback as possible.

If you have any questions or would like additional information, please visit or email us at:

- patients.audentestx.com
- patientadvocacy@audentestx.com

Sincerely,

Kimberly Trant, RN, MBA
Senior Director, Patient Advocacy & Engagement

Edward Conner, M.D.
Senior Vice President and Chief Medical Officer